Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee JH, et al. (2003) .Vitamin C as an antioxidant: evaluation of its role in disease prevention. J Am Coll Nutr; 22 : 18-35.
[2]. Ting HH, Timimi FK, Boles KS, Creager SHJ, Gans P, Creager MA (1996) .Vitamin C improves endothelium dependent vasodilation in patients with non-insulin dependent diabetes mellitus. J Clin Invest 97: 22-8.
[3].Afkhami-Ardekani M, Vahidi AR, Borjian L, Borjian L (2003). Effect of vitamin C supplement on glycosylated hemoglobin in patients with type 2 diabetes. J Shah Sad Univ 10 : 15-8.
[4].Simom JA (1992). Vitamin C and cardiovascular disease: a review. J Am Coll Nutr 11 : 107-25.
[5]. Ness AR, Khaw KT, Bingham S, Day NE (1996) .Vitamin C status and serum lipids. Eur J Clin Nutr 50 : 724-9.
[6].Chen MS, Hutchinson ML, Pecoraro RE, Lee WY, Labbe RF (1991) .Hyperglycemic-induced intracellular depletion of ascorbic acid content in adults with insulin-dependent diabetes mellitus consuming adequate dietary vitamin C. Metabolism 40 : 146-9.
[7]. Dyer RG, Stewart MW, Metcheson J, George K, Alberti MM, Laker MF, et al. (1997) .Ketocholesterol, a specific indicator of lipoprotein oxidation and malondialdehyde in non-insulin dependent diabetes and peripheral vascular diasease. Clin Chim Acta 260 : 1-13.
[8]. Evans M, Anderson RA, Smith JC, Khan N, Graham JM, Thomas AW, et al.( 2003) . Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus. Eur J Clin Invest 33 : 231-8.
[9].Tousoulis D, Antoniades C, Tountas C, Bosinkou E, Kotsopoulou M, Toutouzas P, et al.(2003) .Vitamin C affects thrombosis/fibrinolysis system and reactive hyperemia patients with type 2 diabetes and coronary artery diseases. Diabetes Care 26 : 2749-53.
[10]. Moriarity JT, Folsom AR, Iribarren C, Nieto FJ, Rosamond WD (2000). Serum Uric Acid and Risk of Coronary Heart Disease: Atherosclerosis Risk in Communities (ARIC) Study. Annals of Epid 10(3):136-143.
[11]. So A, Thorens B (2010). Uric acid transport and disease. J. Clin. Invest 120(6):1791-1799.
[12]. Koenig W, Meisinger C (2008). Uric acid, type 2 diabetes, and cardiovascular diseases: Fueling the common soil hypothesis? Clin Chem 54(2):231-233.
[13]. Culleton BF, Larson MG, KannelWB, Levy D (1999). Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 131: 7–13.
[14]. Fang J, Alderman MH (2000). Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992: National Health and Nutrition Examination Survey. JAMA 283:2404–2410.
[15]. Niskanen LK, Laaksonen DE, Nyyssönen K, et al (2004). Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch. Intern. Med 164:1546–1551.
[16]. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH (2009). Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis .Rheum 61:225–232.
[17]. Ioachimescu AG, Brennan DM, Hoar BM, Kashyap SR,Hoogwerf BJ (2007). Serumuric acid, mortality and glucose control in patients with type 2 diabetes mellitus: a PreCIS database study. Diabet. Med 24 : 1369–1374.
[18]. Zoppini G, Targher G, Negri C, et al (2009). Elevated serum uric acid concentrations. independently predict cardiovascular mortality in type 2 diabetic patients. Diabetes Care 32:1716–1720.
[19]. Lee K (2009). Relationship between uric acid and hepatic statuses among Koreans. Diabetes. Metab 35: 447-51.
[20]. Lee YJ, Lee HR, Lee JH, Shin YH, Shim JY (2010). Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin. Chem. Lab. Med 48: 175-80.
[21]. Li Y, Xu C, Yu C, Xu L, Miao M (2009). Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J. Hepatol 50: 1029-34.
[22]. Harita N, Hayashi T, Sato KK, Nakamura Y, Yoneda T, Endo G, et al. (2009). Lower of type 2 diabetes: serum creatinine is a new risk factor the Kansai healthcare study. Diabetes Care, 32:424-426.
[23].Tomaszewski M, Charchar FJ, Maric C, McClure J, Crawford L, Grzeszczak W, et al, (2007). Glomerular hyperfiltration: a new marker of metabolic risk. Kidney International 71:816-821.
[24]. Lorenzo C, Nath SD, Hanley AJ, Abboud HE, Gelfond JA, Haffner SM (2009). Risk of type 2 diabetes among individuals with high and low glomerular filtration rates. Diabetologia, 52:1290-1297.
[29]. Mogensen CE (1990). Prediction of clinical diabetic nephropathy in IDDM patients. Alternatives to microalbuminuria? Diabetes 39:761.
[30]. Faber M, Kupin W, Krishna, Narins R(1993). The differential diagnosis of acute renal failure. In Lazarus JM, Brenner BM. Acute renal failure. New York. Churchil Livingstone.: 133-192.
[31]. Bataller R, Arroyo V (2000). Fracaso renal agudo asociado a enfermedades hepáticas. Síndrome hepatorenal. In Liaño F, Pascual J. Fracaso renal agudo. Barcelona. Masson.: 103-125:313-326.
[32]. Musso CG, Giordani C, Stonski E, Peralta M, Bonetto A, Jauregui R, Algranati L (2004). Acute renal failure with normal plasma urea levels: a marker proximal tubular dysfunction with diabetes insipidus. biomed. uninet.edu.
[33]. Simon SR, Majumdar SR, Prosser LA, Salem-Schatz S, Warner C, Kleinman K, Miroshnik I, Soumerai SB (2005). Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial. Am J Med;118:521–528.
[34]. Peterson KA, Radosevich DM, O’Connor PJ, Nyman JA, Prineas RJ, Smith SA, Arneson TJ, Corbett VA, Weinhandl JC, Lange CJ, Hannan PJ (2008). Improving diabetes care in practice: findings from the TRANSLATE trial. Diabetes Care; 31:2238–2243.
[35]. Krein SL, Klamerus ML, Vijan S, Lee JL, Fitzgerald JT, Pawlow A, Reeves P, Hayward RA (2004). Case management for patients with poorly controlled diabetes: a randomized trial. Am. J. Med 116:732–739.
[36]. Roumie CL, Elasy TA, Greevy R, Griffin MR, Liu X, Stone WJ, Wallston KA, Dittus RS, Alvarez V, Cobb J, Speroff T (2006). Improving blood pressure control through provider education, provider alerts, and patient education: a cluster randomized trial. Ann. Intern. Med 145:165–175.
[37]. Choma NN, Huang RL, Dittus RS, Burnham KE, Roumie CL (2009). Quality improvement initiatives improve hypertension care among veterans. Circ. Card. Qual. Outcomes 2:392–398.
[38]. Estrada C, Salanitro A, Safford M, Curry W, Williams J, Ovalle F, Payne-Foster P, Kim Y, Houston T, Allison JA (2010). cluster-randomized trial of a web-based physician intervention to improve diabetes care (Abstract). J. Invest. Med 58:512.
[39]. Huggett AST, Nixon DA (1957). Use of glucose oxidase peroxidase and O-dianisine in the determination of blood and urine glucose. Lancet 2:368 –370.
[40]. Mustafa K (2004). Simultaneous Determination of Ascorbic Acid and Free Malondialdehyde in Human Serum by HPLC-UV. LCGC ASIA PACIFIC 7-2:36-38.
[41]. American Diabetes Association (2010). Executive summary: standards of medical care in diabetes—2010. Diabetes Care 33 (Suppl. 1):S4–S10,
[42]. Yasunori T, Haruhiko O, Mie K, et al (2008). Hyperresistinemia Is Associated With Coexistence of Hypertension and Type 2 Diabetes. Hypertension 51:534-539.
[43]. Nabil M, Intissar E, Molka C, et al (2007). MTHFR C677T and A1298C gene polymorphisms and
hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diab. Res. Clin. Prac. 75 :99–106.
[44]. Kramer CK, vonMu D, Jassal SK & E. Barrett-Connor (2010). A prospective study of uric acid by glucose tolerance status and survival: the Rancho Bernardo Study. J. I. Med. 267; 561–566.
[45]. Nehal H EL-Said, Abd El Salam F ,Nagwa A E (2011)Retinol Binding Protein 4 And Insulin Resistance In Egyptian Type 2 Diabetics . Aust. J. Basic & Appl. Sci. 5(10): 265-271
[46]. Morteza A, Yaser J , Arash AN ,et al, (2012) .Urea and Oxidative Stress in Type 2 Diabetes. J. Metab. Synd. 1(2):1-5
[47]. Surapon T, Praparporn P, Orathai T, Viruch S (2009). Serum Levels of Malondialdehyde in Type 2 Diabetes Mellitus Thai Subjects. Siriraj. Med. J. 61(1):20-23.
[48]. Tuomilehto J, Zimmet P, Wolf E, Taylor R, Ram P, King H (1988). Plasma uric acid level and its association with diabetes mellitus and some biological parameters in a biracial population of Fiji. Am. J. Epidemiol. 127: 321–336.
[49]. Herman J.B, Medalie J.H. (1976). Goldbourt, Diabetes, prediabetes and uricaemia. Diabetologia 12: 47–52.
[50]. Golembiewska E, Ciechanowski K, Safranow K, Kedzierska K, Kabat-Kopersk J (2005). Renal handling of uric acid in patients with type 1 diabetes in relation to glycemic control. Arch. Med. Res. 36 32-35.
[51]. Shabana S, Sireesha M, Satyanaryana U (2012). Uric Acid in Relation to Type 2 Diabetes Mellitus Associated with Hypertension. J. Clin. Diagn. R. 6(7): 1140-1143.
[52]. Beatriz GS, Andreia B, Carisi A et al , (2000). Increased Plasma Levels of Endothelin 1 and von Willebrand Factor in Patients With Type 2 Diabetes and Dyslipidemia . Diabetes Care 23( 9):1395-1400 .
[53]. Hairong N ,Yanhu D, Weiguo G et al , (2006). Diabetes associated with a low serum uric acid level in
a general Chinese population. D. R. Clin.Prac.76 (2007): 68–74
[54]. Gopaul N.K, Manraj M.D, Hebe A, Lee Kwai Yan S, Johnston A, Carrier M.J, et al., (2001). Oxidative stress could precede with impaired glucose metabolism. Diabetologia 44 :706–712.
[55]. D. Konukoglu, E. Dogan, M.S. Turhan, H. Husrev Hatemi, (2003). Impaired glucose tolerance: its relevance to early endothelial dysfunction, Horm. Metab. Res. 35 607–610.
[56]. K. Nyyssonen, E. Porkkala-Sarataho, J. Kaikkonen, T. Salinen J (1997). Ascorbate and urate are the strongest determinants of plasma antioxidative capacity and serum lipid resistance to oxidation in Finnish men. Atherosclerosis130 :223–233.
[57]. Bankir L, Trinh-Trang-Tan M (2000). Urea and the kidney. In Brenner B, The Kidney. Philadelphia. W.B. Saunders 637-679
[58]. Robertson G, Berl T (2000). Pathophysiology of water metabolism. In Brenner B, The Kidney. Philadelphia. W.B. Saunders 1996: 873-928
[59]. Kunying Z, Li L, Xuyang C, Jie D, Qiuming G , Li Z (2011). Low levels of vitamin C in dialysis patients is associated with decreased prealbumin and increased C-reactive protein. BMC Nephrology 12:18.
[60]. Yoon JW, Pahl MV, Vaziri ND (2007). Spontaneous leukocyte activation and oxygen-free radical generation in end-stage renal disease. Kid. Int 71(2):167-172.
[61]. Carr A, Frei B (2000). The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. F. R. Biol. Med 28:1806–1814.
[62]. Sinclair AJ, Taylor PB, Lunec J, Girling AJ, Barnett AH (1994). Low plasma ascorbate levels in patients with type 2 diabetes mellitus consuming adequate dietary vitamin C. Diabet. Med11:893–898.
[63]. Bode AM, Yavarow CR, Fry DA, Vargas T (1993). Enzymatic basis for altered ascorbic acid and dehydroascorbic acid levels in diabetes. Biochem. Biophys. Res. Commun 191:1347–1353.
[64]. West IC (2000). Radicals and oxidative stress in diabetes. Diabet Med,17: 171–180.
[65]. Jackson TS, Xu A, Vita JA, Keaney JF (1998). Ascorbate prevents the interaction of superoxide and nitric oxide only at very high physiological concentrations. Circ. Res 83:916–922.
[66]. Grundy SM (1997). Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circ 95:1–4.
[67]. Carr AC, Frei B (1999). Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am. J. Clin. Nutr 69:1086–1107.
[68]. Baker TA, Milstien S, Katusic ZS (2001). Effect of vitamin C on the availability of tetrahydrobiopterin in human endothelial cells. J. Card. Pharm 37:333–338.
[69]. Murphy ME (1999). Ascorbate and dehydroascorbate modulate nitric oxideinduced vasodilations of rat coronary arteries. J. Card. Pharm 34:295–303.
[70]. Paolisso G, Balbi V, Volpe C, Varricchio G, Gambardella A, Saccomanno F, Ammendola S, Varricchio M, D’Onofrio F (1995). Metabolic benefits deriving from chronic vitamin C supplementation in aged noninsulin dependent diabetics. J. Am. Coll. Nutr. 14:387–392.
[71]. Hirashima O, Kawano H, Motoyama T, Hirai N, Ohgushi M, Kugiyama K, Ogawa H, Yasue H (2000). Improvement of endothelial function and insulin sensitivity with vitamin C in patients with coronary spastic angina: possible role of reactive oxygen species. J. Am. Coll. Cardiol. 35: 1860–1866.
[72]. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD (1994). Insulinmediated skeletal muscle vasodilation is nitric oxide dependent: a novel action of insulin to increase nitric oxide release. J. Clin. Invest. 94: 1172–1179.
[73]. International Diabetes Federation and the International Society of Nephrology. Diabetes and Kidney Disease. Time to Act (2003).
[74]. Nnodim , Opara AU (2012). The Plasma Vitamin C and E Status in Type II Diabetes with Malaria in Owerri, Nigeria. Pak. J. Nutr 11 (1): 62-63.
[75]. Jyoti MS, Uchita V, Moulick N (2007). Association Of Poor Glycemic Control With Increased Lipid Peroxidation And Reduced Antioxidant Vitamin Status In Diabetic Neuropathy. I. J. Endo 3 (2):210-216.
[76]. Onyesom I, Agho JE, Osioh H. E (2011). Levels of antioxidant vitamins in newly diagnosed cases of
type 2 diabetes mellitus in South Eastern Nigeria. Afr. J. Pharm. Pharmacol 5(150): 1787-1791.